Clinical Trials
10 trialsNCT04302025 2026-05-22
NAUTIKA1
Genentech, Inc.
Phase 2 Recruiting
NCT03337698 2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Terminated
NCT03202940 2026-05-08
A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC
Massachusetts General Hospital
Phase 1/2 Active not recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03600701 2025-10-07
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03989115 2023-06-26
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Phase 1/2 Completed
NCT02457793 2018-11-20
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed